Hologic

The company said that its Aptima HIV-1 molecular test utilizes a dual-target approach against highly conserved regions in the HIV genome.

Hologic designed its scalable AI-based cytology platform to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.

According to some analysts, the selloff in IVD company shares may be an overreaction, and SARS-CoV-2-related testing will be needed for some time in the future. 

The firm said that its molecular diagnostics revenues grew almost fivefold year over year, based on strong global demand for its SARS-CoV-2 molecular assays.

Hologic said that the contract will support its efforts to scale up to providing 13 million molecular tests per month for the US market by January 2022.

The firm said that the FDA further amended an EUA for the Aptima SARS-CoV-2 assay to include the firm's pooling protocol for symptomatic testing.

The notes are general senior unsecured obligations of Hologic guaranteed by certain domestic subsidiaries and expire on Feb. 15, 2029.

The firm said being able to test asymptomatic people with its Panther Fusion SARS-CoV-2 assay could play an important role in reopening the economy.

Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375 percent senior unsecured notes due in 2025.